A real-world evaluation of tislelizumab in patients with head and neck cancer

CONCLUSIONS: Tislelizumab demonstrated promising efficacy and tolerability in patients with HNSCC or NPC in a real-world setting, consistent with previous reports.PMID:38482433 | PMC:PMC10928599 | DOI:10.21037/tcr-23-1502

Source: Cell Research - March 14, 2024 Category: Cytology Authors: Baomin Zheng Zhou Huang Weixin Liu Dan Zhao Xiaolong Xu Shaowen Xiao Yan Sun Weihu Wang Source Type: research